You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 791 A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with relapsed or refractory classic hodgkin lymphoma (cHL)

Article metrics

Article menu

Download PDFPDF

Late-breaking abstracts
Clinical trials completed
791 A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with relapsed or refractory classic hodgkin lymphoma (cHL)

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020178028
Dec 202040011
Jan 20213908
Feb 202140012
Mar 202190015
Apr 202176018
May 202126011
Jun 2021009
Jul 20210013
Aug 20210017
Sep 20211019
Oct 202134021
Nov 202148023
Dec 20219206
Jan 20223806
Feb 20222609
Mar 20222603
Apr 20226209
May 20226605
Jun 20223004
Jul 20221401
Aug 20221803
Sep 20222602
Oct 20222602
Nov 20222001
Dec 20222003
Jan 20233202
Feb 20234002
Mar 20232804
Apr 20231608
May 20231002
Jun 20231802
Jul 20232606
Aug 20231401
Sep 2023200
Oct 20231002
Nov 20231801
Dec 20231801
Jan 2024601
Feb 20241402
Mar 20243403
Apr 20241802
May 20243600
Jun 20244803
Jul 20245001
Aug 20243600
Sep 20243003
Oct 20242403
Nov 20242006
Dec 20242002
Jan 20251409
Feb 2025201
Apr 2025003
May 2025002
Jun 2025003
Total16200334